

FDA Update on Infections Associated with Reprocessed Duodenoscopes

HICPAC


May 16, 2019

Shani Haugen, Ph.D., Microbiologist
Center for Devices and Radiological Health
U.S. Food and Drug Administration

Infections Associated with Reprocessed Duodenoscopes



- In September 2013, CDC alerted FDA of association of multi-drug resistant organism infections and duodenoscopes
- Since that time, healthcare facilities have reported infections associated with duodenoscope use




FDA Actions:

Revised Reprocessing Instructions



- FDA worked with duodenoscope manufacturers as they updated and validated their reprocessing instructions
- Updated instructions include additional cleaning and disinfection steps for the elevator recess

FDA Actions: Device Design



- FDA cleared duodenoscopes with design modifications to the elevator channel sealing mechanism

- The labeling was also revised to recommend annual inspection to identify wear and tear



- New duodenoscope device designs

FDA Actions: Outreach



- February 2015 FDA Safety Communication
- 2015 FDA Advisory Committee Meeting
- 2015 HICPAC Meeting

The screenshot shows the FDA website header with the logo and "U.S. FOOD & DRUG ADMINISTRATION". The main heading is "Design of Endoscopic Retrograde Cholangiopancreatography (ERCP) Duodenoscopes May Impede Effective Cleaning: FDA Safety Communication". Below the heading are social media sharing buttons for Facebook (SHARE), Twitter (TWEET), and Email (EMAIL). The text indicates the communication was issued on February 19, 2015, and updated on February 23, 2015, and March 4, 2015. A link is provided for "Updated Information for Healthcare Providers Regarding Duodenoscopes".

- Additional Communications: revised reprocessing instructions, clearance/recall of duodenoscopes, webpage for Infections Associated with Reprocessed Duodenoscopes

Prior FDA Actions: Supplemental Measures



- FDA released a summary of supplemental measures to enhance duodenoscope reprocessing that emerged from the Advisory Committee meeting (August 2015)
- FDA worked with CDC and ASM to develop a protocol for sampling and culturing duodenoscopes (February 2018)



Prior FDA Actions: Regulatory Actions



- FDA conducted directed inspections and issued Warning Letters to duodenoscope manufacturers in 2015
- In October 2015, FDA ordered duodenoscope manufacturers to conduct postmarket surveillance studies
 - Human factors studies and Sampling/culturing studies
 - FDA issued Warning Letters in March 2018 for failing to comply with postmarket surveillance studies


Current Data: Duodenoscope Medical Device Reporting



- In 2018, 3 deaths were reported in the US related to duodenoscopes
- Reports of infections declined from 2015
- There is a continued need to improve the safety of reprocessed duodenoscopes

Duodenoscope MDRs associated with infection, exposure, or device contamination

* Note that the year is when the report was submitted to FDA, not necessarily the date of event



Current Data: Human Factors Validation Testing Report



- Results from human factors studies indicate that reprocessing instructions in current user manuals can be strengthened because they are difficult for reprocessing staff to comprehend and follow
 - Some reprocessing staff missed one or more steps in the process and needed additional training to complete the process properly
 - The descriptions of some of the processing steps in the user manuals were unclear

Current Data:



Interim Sampling and Culturing Results

- Up to 3.6% of properly collected samples tested positive with low to moderate concern organisms > 100 CFU
- Up to 5.4% of properly collected samples tested positive for high concern organisms, defined as organisms that are more often associated with disease, such as *E. coli* and *Pseudomonas aeruginosa*

<https://www.fda.gov/medical-devices/safety-communications/fda-continues-remind-facilities-importance-following-duodenoscopy-reprocessing-instructions-fda>

Literature: Supplemental Measures



- Survey results indicate widespread implementation of supplemental measures to enhance duodenoscope reprocessing (Thaker 2018)
 - Of 249 facilities, 90% implement one or more supplemental measures

Repeat manual
cleaning and HLD
157/249 (63%)

Surveillance
microbiological
culturing
133/249 (53%)

Liquid chemical
sterilization
86/249 (35%)

Ethylene oxide
gas sterilization
30/249 (12%)

Literature: Supplemental Measures



- Results of the sampling/culturing postmarket surveillance study are consistent with published reports (Bartles 2018, Rauwers 2018, Ross 2015, Rex 2018, Snyder 2017, Visrodia 2017)
 - Some percentage of duodenoscopes remain contaminated after use
- Repeat HLD does not significantly impact the contamination rate compared to single HLD (Bartles 2018, Snyder 2017)

Reprocessing Validation

Process	Test Organism Inoculum	Minimum bacterial count	Test Cycle	Test Endpoints
High Level Disinfection	<i>Mycobacterium terrae</i> (in soil)	6 log ₁₀	Full cycle (minimum cycle conditions)	6 log ₁₀ reduction
Liquid Chemical Sterilization	<i>Bacillus atrophaeus</i> spores (in soil)	6 log ₁₀	Full cycle (minimum cycle conditions)	6 log ₁₀ reduction
Ethylene Oxide Sterilization	<i>Bacillus atrophaeus</i> spores (no soil)	6 log ₁₀	Half cycle	Complete microbial inactivation

Literature: Sterilization



- Contamination rates after EO sterilization are **variable** (Naryzhny 2016, Snyder 2017)
- Ethylene oxide sterilization of duodenoscopes led to cessation of outbreaks (Epstein 2015, Smith 2015, Humphries 2017)
- Additional sterilization technologies are in development for duodenoscopes (Molloy-Simard 2019)

FDA Conclusion



- Current practices for reprocessing duodenoscopes are not sufficient to avoid all infections associated with the use of duodenoscopes
- In appropriately selected patients, the benefits of the procedure still outweigh the risks

Questions the FDA is Exploring



What changes could be made to ensure the safer use of duodenoscopes, and how should those changes be implemented, considering potential challenges?

Questions the FDA is Exploring



Given the information provided today,
what level of concern do you have
regarding the safety of reprocessed
duodenoscopes?

Questions the FDA is Exploring



Do you think high level disinfection provides an adequate assurance of safety?

Questions the FDA is Exploring



What are the challenges to sterilizing
duodenoscopes?





FDA Duodenoscope Website: <https://www.fda.gov/medical-devices/reprocessing-reusable-medical-devices/infections-associated-reprocessed-duodenoscopes>

Revised Reprocessing Instructions:

Olympus March 2015: <http://wayback.archive-it.org/7993/20170722213115/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm439999.htm>

Fujifilm December 2015: <http://wayback.archive-it.org/7993/20170722062401/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm478290.htm>

Pentax February 2016: <http://wayback.archive-it.org/7993/20171115052156/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm486772.htm>

Clearance of Modified Duodenoscopes

Olympus January 2016: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm481956.htm>

Fujifilm July 2017: <https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm567793.htm>

Pentax February 2018: <https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm595603.htm>

Additional Resources:

FDA AER website:

<https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ReprocessingofReusableMedicalDevices/ucm483896.htm>

May 2015 Advisory Committee Meeting Summary: <https://wayback.archive-it.org/7993/20170112083625/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/Gastroenterology-UrologyDevicesPanel/UCM447407.pdf>

August 2015 Supplemental Measures to Enhance Duodenoscope Reprocessing: <https://wayback.archive-it.org/7993/20170406123633/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm457132.htm>

October 2015 Postmarket Surveillance Studies: <https://wayback.archive-it.org/7993/20180126064842/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465639.htm>

522 Status: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm>

FDA/CDC/ASM Surveillance Sampling and Culturing Protocol:

<https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/ReprocessingofReusableMedicalDevices/UCM597949.pdf>

References:

Bartles RL, Leggett JE, Hove S, Kashork CD, Wang L, Oethinger M, Baxter L, Brandabur JJ. A randomized trial of single versus double high-level disinfection of duodenoscopes and linear echoendoscopes using standard automated reprocessing. *Gastrointest Endosc*. 2018 Aug;88(2):306-313

<https://www.ncbi.nlm.nih.gov/pubmed/29476847>

Epstein L, Hunter JC, Arwady MA, Tsai V, Stein L, Gribogiannis M, Frias M, Guh AY, Laufer AS, Black S, Pacilli M, Moulton-Meissner H, Rasheed JK, Avillan JJ, Kitchel B, Limbago BM, MacCannell D, Lonsway D, Noble-Wang J, Conway J, Conover C, Vernon M, Kallen AJ. New Delhi metallo- β -lactamase-producing carbapenem-resistant *Escherichia coli* associated with exposure to duodenoscopes. *JAMA*. 2014 Oct 8;312(14):1447-55.

<https://www.ncbi.nlm.nih.gov/pubmed/25291580>

Humphries RM, Yang S, Kim S, Muthusamy VR, Russell D, Trout AM, Zaroda T, Cheng QJ, Aldrovandi G, Uslan DZ, Hemarajata P, Rubin ZA. Duodenoscope-Related Outbreak of a Carbapenem-Resistant *Klebsiella pneumoniae* Identified Using Advanced Molecular Diagnostics. *Clin Infect Dis*. 2017 Oct 1;65(7):1159-1166.

<https://www.ncbi.nlm.nih.gov/pubmed/29579235>

Molloy-Simard V, Lemyre JL, Martel K, Catalone BJ. Elevating the standard of endoscope processing: Terminal sterilization of duodenoscopes using a hydrogen peroxide-ozone sterilizer. *Am J Infect Control*. 2019

Mar;47(3):243-250. <https://www.ncbi.nlm.nih.gov/pubmed/30442443>

Naryzhny I, Silas D, Chi K. Impact of ethylene oxide gas sterilization of duodenoscopes after a carbapenem-resistant *Enterobacteriaceae* outbreak. *Gastrointest Endosc*. 2016 Aug;84(2):259-62.

<https://www.ncbi.nlm.nih.gov/pubmed/26855298>

References:

Rauwers AW, Voor In 't Holt AF, Buijs JG, de Groot W, Hansen BE, Bruno MJ, Vos MC. High prevalence rate of digestive tract bacteria in duodenoscopes: a nationwide study. *Gut*. 2018 Sep;67(9):1637-1645.

<https://www.ncbi.nlm.nih.gov/pubmed/29636382>

Rex DK, Sieber M, Lehman GA, Webb D, Schmitt B, Kressel AB, Bang JY, Easler J, McHenry L, El-Hajj I, Fogel E, Watkins J, Sherman S. A double-reprocessing high-level disinfection protocol does not eliminate positive cultures from the elevators of duodenoscopes. *Endoscopy*. 2018 Jun;50(6):588-596.

<https://www.ncbi.nlm.nih.gov/pubmed/29237202>

Ross AS, Baliga C, Verma P, Duchin J, Gluck M. A quarantine process for the resolution of duodenoscope-associated transmission of multidrug-resistant *Escherichia coli*. *Gastrointest Endosc*. 2015 Sep;82(3):477-83.

<https://www.ncbi.nlm.nih.gov/pubmed/26092616>

Smith ZL, Dua A, Saeian K, Ledebouer NA, Graham MB, Aburajab M, Ballard DD, Khan AH, Dua KS. A Novel Protocol Obviates Endoscope Sampling for Carbapenem-Resistant *Enterobacteriaceae*: Experience of a Center with a Prior Outbreak. *Dig Dis Sci*. 2017 Nov;62(11):3100-3109.

<https://www.ncbi.nlm.nih.gov/pubmed/28681083>

Snyder GM, Wright SB, Smithey A, Mizrahi M, Sheppard M, Hirsch EB, Chuttani R, Heroux R, Yassa DS, Olafsdottir LB, Davis RB, Anastasiou J, Bapat V, Bidari K, Pleskow DK, Leffler D, Lane B, Chen A, Gold HS, Bartley A, King AD, Sawhney MS. Randomized Comparison of 3 High-Level Disinfection and Sterilization Procedures for Duodenoscopes. *Gastroenterology*. 2017 Oct;153(4):1018-1025.

<https://www.ncbi.nlm.nih.gov/pubmed/28711629>

References:

Thaker AM, Muthusamy VR, Sedarat A, Watson RR, Kochman ML, Ross AS, Kim S. Duodenoscope reprocessing practice patterns in U.S. endoscopy centers: a survey study. *Gastrointest Endosc.* 2018 Aug;88(2):316-322.

<https://www.ncbi.nlm.nih.gov/pubmed/29684387>

Visrodia K, Hanada Y, Pennington KM, Tosh PK, Topazian MD, Petersen BT. Duodenoscope reprocessing surveillance with adenosine triphosphate testing and terminal cultures: a clinical pilot study. *Gastrointest Endosc.* 2017 Jul;86(1):180-186.

<https://www.ncbi.nlm.nih.gov/pubmed/28396277>

U.S. Food and Drug Administration. FDA Guidance: Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling – Guidance for Industry and Food and Drug Administration Staff. Document issued March 17, 2015, updated June 9, 2017. <https://www.fda.gov/media/80265/download>